TriSalus Life Sciences, Inc. (TLSI)
| Market Cap | 291.25M +17.3% |
| Revenue (ttm) | 45.08M +25.2% |
| Net Income | -57.25M |
| EPS | -1.15 |
| Shares Out | 61.57M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 86,871 |
| Open | 4.920 |
| Previous Close | 5.000 |
| Day's Range | 4.920 - 5.130 |
| 52-Week Range | 2.200 - 7.950 |
| Beta | 0.44 |
| Analysts | Strong Buy |
| Price Target | 10.00 (+111.42%) |
| Earnings Date | Aug 6, 2026 |
About TLSI
TriSalus Life Sciences, Inc. engages in the research, development, and commercialization of drug delivery technology platform and immuno-oncology therapeutics to improve outcomes for patients with difficult-to-treat liver and pancreatic cancers in the United States. It offers Pressure-Enabled Drug Delivery (PEDD) infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device... [Read more]
Financial Performance
In 2025, TriSalus Life Sciences's revenue was $45.15 million, an increase of 53.41% compared to the previous year's $29.43 million. Losses were -$69.69 million, 109.7% more than in 2024.
Financial StatementsAnalyst Summary
According to 4 analysts, the average rating for TLSI stock is "Strong Buy." The 12-month stock price target is $10.0, which is an increase of 111.42% from the latest price.
News
TriSalus Life Sciences initiated with a Buy at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth initiated coverage of TriSalus Life Sciences (TLSI) with a Buy rating and $11 price target TriSalus is a commercial-stage device with an FDA-cleared TriN...
TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences to Participate in the H.C. Wainwright & Company 28th Annual Global Investment Conference.
TriSalus Life Sciences Transcript: Canaccord Genuity's 46th Annual Growth Conference
A smart valve catheter technology is driving improved drug delivery and outcomes in solid tumors, with imminent FDA clearance for TriNav ADVANCE expected to expand the addressable market by 20%. Strong clinical evidence, new reimbursement codes, and a scaled sales force position the company for significant near-term growth.
TriSalus Life Sciences reports Q2 EPS (16c), consensus (16c)
Reports Q2 revenue $11.4M, consensus $10.27M. “We delivered a second quarter marked by year-over-year and strong sequential growth. We continued strengthening our foundation to drive future expansion ...
TriSalus Life Sciences sees FY26 revenue $54M-$57M, consensus $52.4M
The Company is maintaining its full-year 2026 revenue guidance of $54M-$57M, consistent with the range set in the first quarter and representing growth of 19% to 26% compared to full…
TriSalus Life Sciences Earnings Call Transcript: Q2 2026
Q2 2026 revenue grew to $11.4M, driven by TriNav demand and commercial expansion. CMS approved a G-code for OBL reimbursement, broadening market access. Full-year revenue guidance of $54–$57M was reiterated, with sequential growth and cost discipline expected.
TriSalus Life Sciences Earnings release: Q2 2026
TriSalus Life Sciences released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
TriSalus Life Sciences Quarterly report: Q2 2026
TriSalus Life Sciences has published its Q2 2026 quarterly earnings report on August 6, 2026.
TriSalus Life Sciences Reports Second Quarter 2026 Results
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational...
TriSalus Life Sciences to Participate in the Canaccord Genuity 46th Annual Growth Conference
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences® Inc. (Nasdaq: TLSI) (“TriSalus” or the “Company”), an oncology company integrating novel delivery technology with standard of care therapie...
TriSalus Life Sciences to Host Second Quarter 2026 Financial Results Conference Call
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard-of-care therapies and an inves...
TriSalus Life Sciences to host KOL event featuring RWE on PEDD
TriSalus Life Sciences (TLSI) will host a virtual key opinion leader event on Wednesday, June 24, 2026 at 8:00 AM ET. The event will feature the findings of a newly…
TriSalus Life Sciences to Host Virtual KOL Event on June 24 Featuring New Real-World Evidence for Pressure-Enabled Drug Delivery™ in Liver Cancer
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI), an oncology company integrating novel delivery technology with standard-of-care therapies and an investigational immun...
TriSalus Life Sciences price target lowered to $8 from $10 at Lake Street
Lake Street lowered the firm’s price target on TriSalus Life Sciences (TLSI) to $8 from $10 and keeps a Buy rating on the shares. The firm reduced its 2026 and…
TriSalus Life Sciences reports Q EPS 3c, one estimate (16c)
Reports Q1 revenue $8.9M, consensus $10.4M. “The first quarter marked an important strategic inflection point for TriSalus as we significantly strengthened our commercial infrastructure, expanded the ...
TriSalus Life Sciences Earnings Call Transcript: Q1 2026
Q1 2026 saw a deliberate commercial expansion, leading to a temporary revenue dip but positioning for multi-year growth. Landmark PEDD study validated significant clinical and economic benefits, while 2026 revenue guidance was revised to $54–57 million due to FDA delays and transition costs.
TriSalus Life Sciences Earnings release: Q1 2026
TriSalus Life Sciences released its Q1 2026 earnings on May 12, 2026, summarizing the period's financial results.
TriSalus Life Sciences Quarterly report: Q1 2026
TriSalus Life Sciences has published its Q1 2026 quarterly earnings report on May 12, 2026.
TriSalus Life Sciences Reports First Quarter 2026 Results Demonstrating Commercial and Clinical Progress for Facilitating Long-Term Growth
DENVER--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its investigational...
TriSalus announces journal publication of PEDD study
TriSalus Life Sciences (TLSI) announced the publication of the largest real-world evidence study to date evaluating the clinical and economic impact of Pressure-Enabled Drug Delivery technology used i...
Real-World PEDD Study Published in the Journal of Comparative Effectiveness Research Shows Improved Clinical Outcomes and Meaningful Charge Avoidance
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its inv...
TriSalus Life Sciences Announces Launch of PREDICTT Clinical Trial Evaluating Pressure-Enabled Drug Delivery in Liver Tumors
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its inv...
TriSalus Life Sciences to Host First Quarter 2026 Financial Results Conference Call
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its inv...
TriSalus Life Sciences Slides: Investor presentation
TriSalus Life Sciences has posted slides in relation to its latest quarterly earnings report, which was published on April 15, 2026.
TriSalus Life Sciences to Present New Data at the 2026 Society of Interventional Radiology Annual Scientific Meeting
WESTMINSTER, Colo.--(BUSINESS WIRE)--TriSalus Life Sciences, Inc. (Nasdaq: TLSI) (the “Company”), an oncology company integrating novel delivery technology with standard of care therapies, and its inv...